Yahoo
LSE - Delayed Quote GBp

Smith & Nephew plc (SN.L)

1,107.50 -13.50 (-1.20%)
At close: October 30 at 4:35:13 PM GMT
Chart Range Bar
Loading chart for SN.L
  • Previous Close 1,121.00
  • Open 1,108.00
  • Bid 1,105.50 x --
  • Ask 1,106.00 x --
  • Day's Range 1,088.00 - 1,118.50
  • 52 Week Range 980.40 - 1,426.59
  • Volume 4,298,885
  • Avg. Volume 2,973,850
  • Market Cap (intraday) 9.27B
  • Beta (5Y Monthly) 0.67
  • PE Ratio (TTM) 20.14
  • EPS (TTM) 0.55
  • Earnings Date Aug 4, 2026
  • Forward Dividend & Yield 0.29 (2.66%)
  • Ex-Dividend Date Oct 1, 2026
  • 1y Target Est 1,247.16

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

www.smith-nephew.com

17,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Medical Devices

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is FTSE 100 (^FTSE) .

YTD Return

SN.L
10.55%
FTSE 100 (^FTSE)
8.04%

1-Year Return

SN.L
18.96%
FTSE 100 (^FTSE)
9.94%

3-Year Return

SN.L
22.12%
FTSE 100 (^FTSE)
46.43%

5-Year Return

SN.L
11.63%
FTSE 100 (^FTSE)
48.25%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 1.6B
Earnings --
Profit Margin 0.00%

Q2

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
500M
1B
2B
0.0%

Analyst Insights

View More

Analyst Price Targets

1,055.78
1,247.16 Average
1,107.50 Current
1,550.51 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    10.08%

  • Return on Assets (ttm)

    5.16%

  • Return on Equity (ttm)

    11.85%

  • Revenue (ttm)

    6.3B

  • Net Income Avi to Common (ttm)

    635M

  • Diluted EPS (ttm)

    0.55

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    754M

  • Total Debt/Equity (mrq)

    73.07%

  • Levered Free Cash Flow (ttm)

    1.06B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: